Unraveling the active conformation of urotensin II.
暂无分享,去创建一个
Ettore Novellino | Pietro Campiglia | Paolo Rovero | Paolo Grieco | E. Novellino | P. Grieco | P. Campiglia | A. Carotenuto | P. Rovero | Alfonso Carotenuto
[1] K. Wüthrich. NMR of proteins and nucleic acids , 1988 .
[2] S. Awasthi,et al. "Teflon-coated peptides": hexafluoroacetone trihydrate as a structure stabilizer for peptides. , 1997, Biopolymers.
[3] Ethan S. Burstein,et al. Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2- (dimethylamino)ethyl)isochroman-1-one (AC-7954). , 2002 .
[4] D. Sargent,et al. Membrane lipid phase as catalyst for peptide-receptor interactions. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[5] S. Douglas,et al. Human urotensin‐II is a potent spasmogen of primate airway smooth muscle , 2000, British journal of pharmacology.
[6] G Vassart,et al. Current developments in G-protein-coupled receptors. , 1991, Current opinion in cell biology.
[7] M. Billeter,et al. MOLMOL: a program for display and analysis of macromolecular structures. , 1996, Journal of molecular graphics.
[8] S. Douglas,et al. Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. , 2000, Trends in cardiovascular medicine.
[9] V. Hruby,et al. Relative conformational rigidity in oxytocin and (1-penicillamine)-oxytocin: a proposal for the relationship of conformational flexibility to peptide hormone agonism and antagonism. , 1977, Proceedings of the National Academy of Sciences of the United States of America.
[10] K. Wüthrich,et al. Torsion angle dynamics for NMR structure calculation with the new program DYANA. , 1997, Journal of molecular biology.
[11] J. Thornton,et al. PROMOTIF—A program to identify and analyze structural motifs in proteins , 1996, Protein science : a publication of the Protein Society.
[12] P. Molenaar,et al. Cardiostimulant effects of urotensin‐II in human heart in vitro , 2001, British journal of pharmacology.
[13] H. Sarau,et al. Differential vasoconstrictor activity of human urotensin‐II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey , 2000, British journal of pharmacology.
[14] H. Heng,et al. Cloning and chromosomal mapping of three novel genes, GPR9, GPR10, and GPR14, encoding receptors related to interleukin 8, neuropeptide Y, and somatostatin receptors. , 1995, Genomics.
[15] S. Douglas,et al. Contractile responses to human urotensin‐II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat , 2000, British journal of pharmacology.
[16] Ettore Novellino,et al. Design, synthesis, conformational analysis, and biological studies of urotensin-II lactam analogues. , 2002, Bioorganic & medicinal chemistry.
[17] H. Dyson,et al. Polypeptide backbone resonance assignments and secondary structure of Bacillus subtilis enzyme IIIglc determined by two-dimensional and three-dimensional heteronuclear NMR spectroscopy. , 1991, Biochemistry.
[18] Richard R. Ernst,et al. Multiple quantum filters for elucidating NMR coupling networks , 1982 .
[19] E. Novellino,et al. A new, potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge. , 2002, Journal of medicinal chemistry.
[20] Ad Bax,et al. MLEV-17-based two-dimensional homonuclear magnetization transfer spectroscopy , 1985 .
[21] K Wüthrich,et al. The program XEASY for computer-supported NMR spectral analysis of biological macromolecules , 1995, Journal of biomolecular NMR.
[22] Jilly F. Evans,et al. Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. , 1999, Biochemical and biophysical research communications.
[23] S. Douglas. Human urotensin-II as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'? , 2003, Current opinion in pharmacology.
[24] L. Moroder,et al. Peptide hormone-membrane interactions. Intervesicular transfer of lipophilic gastrin derivatives to artificial membranes and their bioactivities. , 1993, Biochimica et biophysica acta.
[25] A. Davenport,et al. Is urotensin‐II the new endothelin? , 2002, British journal of pharmacology.
[26] P. V. von Hippel,et al. Calculation of protein extinction coefficients from amino acid sequence data. , 1989, Analytical biochemistry.
[27] A. Hagler,et al. Derivation of force fields for molecular mechanics and dynamics from ab initio energy surfaces. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[28] D. Coy,et al. Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists. , 2002, European journal of pharmacology.
[29] Yumiko Saito,et al. Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction , 1999, Nature Cell Biology.
[30] H. Sarau,et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 , 1999, Nature.
[31] T. Klabunde,et al. Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. , 2002, Journal of medicinal chemistry.
[32] C. Yu,et al. NMR and dynamical simulated annealing studies on the solution conformation of urotensin II. , 1994, Biochimica et biophysica acta.
[33] E. Novellino,et al. Recent structure-activity studies of the peptide hormone urotensin-II, a potent vasoconstrictor. , 2004, Current medicinal chemistry.
[34] Richard R. Ernst,et al. Investigation of exchange processes by two‐dimensional NMR spectroscopy , 1979 .